Biogen ALS Drug Showed No Benefit, O'Neill Says

Your next video will start in

Recommended Videos

  • Info

  • Comments

Jan. 3 (Bloomberg) -- Gilmore O’Neill, vice president of clinical development at Biogen Idec Inc., talks with Bloomberg's Meg Tirrell about the company's announcement that its experimental drug for amyotrophic lateral sclerosis failed to help patients in a clinical trial. Biogen sank 1.4 percent to $147.86 at 4 p.m. New York time after saying it will end development of the medicine for ALS, also known as Lou Gehrig’s disease. (Source: Bloomberg)


BTV Channel Finder


ZIP is required for U.S. locations

Bloomberg Television in   change